PMID- 36758269
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230426
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 192
DP  - 2023 Apr 1
TI  - Subclinical Leaflet Thrombosis After Balloon versus Self-Expandable Transcatheter 
      Aortic Valve Implantation.
PG  - 88-97
LID - S0002-9149(23)00016-4 [pii]
LID - 10.1016/j.amjcard.2023.01.015 [doi]
AB  - Hypoattenuated leaflet thickening (HALT) has been recognized as one of the 
      complications after transcatheter aortic valve implantation and may promote 
      structural valve degeneration and increase the risk of cerebrovascular events. 
      The 2 main types of available transcatheter heart valves (THVs), the 
      balloon-expandable (BE) and the self-expanding (SE), are interchangeably used in 
      clinical practice despite substantial design differences. There is unclear 
      evidence on whether these 2 different THV models are achieving similar or 
      different rates of subclinical leaflet thrombosis/HALT. A systematic search of 
      electronic databases was conducted to identify studies that reported the 
      incidence of HALT between SE THVs and BE THVs. The Mantel-Haenszel method was 
      used to calculate the 95% confidence interval and pooled risk ratio with a 
      random-effects model. A total of 126 records were identified, of which 22 studies 
      comprising 14,401 patients were included in our final analysis. Among 5,951 
      patients receiving SE THVs, 194 (3.2%) developed HALT, compared with 8,450 
      patients receiving BE THVs, of whom 484 (5.7%) developed HALT. There was a 
      statistically significant decrease in the risk of developing HALT in patients 
      receiving SE THVs compared with those receiving BE THVs (risk ratio 0.75, 95% 
      confidence interval 0.59 to 0.95, I(2) 32%, p = 0.02). In conclusion, could 
      potentially reduce the risk of HALT/subclinical leaflet thrombosis.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Bansal, Agam
AU  - Bansal A
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Agarwal, Siddharth
AU  - Agarwal S
AD  - Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
FAU - Braghieri, Lorenzo
AU  - Braghieri L
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Jaggi, Connor
AU  - Jaggi C
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Bakhtadze, Beka
AU  - Bakhtadze B
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Prasada, Sameer
AU  - Prasada S
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Reed, Grant W
AU  - Reed GW
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Puri, Rishi
AU  - Puri R
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Yun, James
AU  - Yun J
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Menon, Venu
AU  - Menon V
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Krishnaswamy, Amar
AU  - Krishnaswamy A
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Kapadia, Samir R
AU  - Kapadia SR
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, Cleveland, Ohio. Electronic address: kapadis@ccf.org.
LA  - eng
PT  - Journal Article
DEP - 20230207
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - IM
MH  - Humans
MH  - *Transcatheter Aortic Valve Replacement/adverse effects
MH  - Aortic Valve/surgery
MH  - *Aortic Valve Stenosis/surgery
MH  - *Heart Valve Prosthesis/adverse effects
MH  - *Thrombosis/epidemiology
MH  - Prosthesis Design
MH  - Treatment Outcome
COIS- Disclosures The authors have no conflicts of interest to declare.
EDAT- 2023/02/10 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/02/09 18:05
PHST- 2022/11/11 00:00 [received]
PHST- 2022/12/23 00:00 [revised]
PHST- 2023/01/07 00:00 [accepted]
PHST- 2023/02/10 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/02/09 18:05 [entrez]
AID - S0002-9149(23)00016-4 [pii]
AID - 10.1016/j.amjcard.2023.01.015 [doi]
PST - ppublish
SO  - Am J Cardiol. 2023 Apr 1;192:88-97. doi: 10.1016/j.amjcard.2023.01.015. Epub 2023 
      Feb 7.